Johnson and Johnson
Oncology/ Sales and Marketing/ Views & Analysis/ Views & Analysis/ Views and analysis
The top 5 pharma M&A deals of 2020
George Underwood
Gilead, J&J, Johnson and Johnson, M&A, Merck & Co, MSD, Sanofi
0 Comment
Nothing should stand in the way of coronavirus vaccine access, says J&J
George Underwood
coronavavirus vaccine, coronavirus, COVID-19, Janssen, Johnson and Johnson
0 Comment
R&D/ Views & Analysis/ Views and analysis
Johnson & Johnson: Partnering to eliminate disease
George Underwood
J&J, Johnson and Johnson, Oliver Stohlmann, world without disease
0 Comment
Insights/ Sales and Marketing/ Views & Analysis/ Views and analysis
J&J tops the pharma market cap charts – but for how long?
Piotr Wnuk
AbbVie, Amazon, Google, Johnson and Johnson, Merck KGaA, Roche, Takeda, top pharma companies, top pharmaceutical companies
0 Comment
Diabetes/ Diabetes/ Healthcare/ News/ News/ Patients
J&J seals $2.1bn deal on sale of major diabetes devices firm
Joy Persaud
blood glucose monitor, Diabetes, Glucose, J&J, Johnson and Johnson, Platinum Equity
0 Comment
News/ News/ Top pharmaceutical companies
J&J offered $2.7 billion for sterilisation business by Fortive
Linda Banks
ASP, Fortive, infection, J&J, Johnson and Johnson, medical devices, pharma deal, sterilisation
0 Comment
Johnson & Johnson (J&J) has announced that Fortive Corp has made an offer of about $2.7 billion in cash for its Advanced Sterilisation Products (ASP) business.